Immunocore is one of the world’s leading biotechnology companies, with a highly innovative immune-oncology platform technology called ImmTACs.
ImmTACs are a novel class of biologic drugs based on the Company’s proprietary T cell receptor (TCR) technology which have the potential to treat diseases with high unmet medical need including cancer, viral infections and autoimmune diseases.
Immunocore, based on decades of world-leading scientific innovation in the discovery of HLA targets and T cell receptor technology, has a pipeline of wholly-owned and partnered ImmTAC programmes with robust clinical data, validated by collaborations with world-leading pharmaceutical companies.
Immunocore aims to leverage the utility of its platform across a wide range of indications to become a Premier Biotech company and world-leader in its field. Immunocore’s world-leading science and strong IP position has attracted major pharmaceutical companies including Genentech, GlaxoSmithKline, MedImmune, the biologics division of AstraZeneca, via discovery collaborations, as well as a co-discovery and co-development partnership with Lilly.
Founded in 2008 originally out of Oxford University and headquartered outside Oxford, Immunocore now has more than 140 staff. Immunocore is well-funded and owned by a group of long-term private investors.
4 jobs with Immunocore
We are always on the look-out for dynamic, dedicated scientists, both senior and junior, to strengthen our...
Immunocore are setting up a new group (R2D Transition) which will work at the interface between Research and Development...
Immunocore are setting up a new PK group to expand the therapeutic potential of our ImmTAC platform...
Immunocore Limited is an innovative and dynamic biotechnology company whose proprietary T cell receptor technology has the...